VBI Vaccines announces phase 2a trial of VBI-1901 plus AS01B adjuvant system in recurrent glioblastoma
As part of the collaboration, VBI plans to add an additional study arm to Part B of the company’s ongoing, multi-center, open-label Phase 1/2a clinical study targeting recurrent